[Rinsho ketsueki] The Japanese journal of clinical hematology · 2013
[Outcome of patients with relapsed/refractory adult T-cell leukemia-lymphoma after salvage therapy].
Аннотация на английскомСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Taniguchi Hiroaki, Imaizumi Yoshitaka, Makiyama Junya, Itonaga Hidehiro, Ando Koji, Sawayama Yasushi, Imanishi Daisuke, Taguchi Jun, Tsushima Hideki, Hata Tomoko, Hasegawa Hiroo, Hayashi Tomayoshi, Niino Daisuke, Ohshima Koichi, Tsukasaki Kunihiro, Miyazaki Yasushi
Аннотация
We retrospectively analyzed 81 relapsed or refractory adult T-cell leukemia-lymphoma (ATL) patients who received salvage therapy in our institution between 2000 and 2010. These patients had received chemotherapy, radiation, or hematopoietic stem cell transplantation (HSCT) as an initial treatment, and were then given chemotherapy, radiation, HSCT, or donor lymphocyte infusion (DLI) as salvage therapy. Median survival time was 3.9 months. Of 5 long-term survivors, who survived more than 2 years after the first salvage therapy, 4 patients received HSCT or DLI, and the other was given mogamulizumab as the salvage therapy. For patients with relapsed or refractory ATL, HSCT/DLI is a promising treatment for achieving long-term survival. Mogamulizumab may be the good choice for those who are ineligible for HSCT.